NCCN Guidelines® insights: Melanoma, version 3.2016: Featured updates to the NCCN Guidelines

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 14, Issue 8, 2016, Pages 945-958

  Coit, Daniel G ^a   Thompson, John A ^b   Algazi, Alain ^c   Andtbacka, Robert ^d   Bichakjian, Christopher K ^e   Iii, William E Carson ^f   Daniels, Gregory A ^g   Dimaio, Dominick ^h   Fields, Ryan C ⁱ   Fleming, Martin D ^j   Gastman, Brian ^k   Gonzalez, Rene ^l   Guild, Valerie ^m   Johnson, Douglas ⁿ   Joseph, Richard W ^o   Lange, Julie R ^p   Martini, Mary C ^q   Materin, Miguel A ^r   Olszanski, Anthony J ^s   Ott, Patrick ^t   Gupta, Aparna Priyanath ^q   Ross, Merrick I ^u   Salama, April K ^v   Skitzki, Joseph ^w   Swetter, Susan M ^x   Tanabe, Kenneth K ^y   Torres Roca, Javier F ^z   Trisal, Vijay ^aa   Urist, Marshall M ^ab   McMillian, Nicole ^ac   Engh, Anita ^ac   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b SEATTLE CANCER CARE ALLIANCE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^h UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

ⁱ BARNES JEWISH HOSPITAL   (United States)

^j UNIVERSITY OF TENNESSEE   (United States)

^k UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^l UNIVERSITY OF COLORADO   (United States)

^m AIM   (United States)

ⁿ VANDERBILT INGRAM CANCER CENTER   (United States)

^o MAYO CLINIC CANCER CENTER   (United States)

^p JOHNS HOPKINS UNIVERSITY   (United States)

^q NORTHWESTERN UNIVERSITY   (United States)

^r YALE CANCER CENTER   (United States)

^s FOX CHASE CANCER CENTER   (United States)

^t DANA FARBER BRIGHAM AND WOMEN S CANCER CENTER   (United States)

^u UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^v DUKE CANCER INSTITUTE   (United States)

^w ROSWELL PARK CANCER INSTITUTE   (United States)

^x STANFORD CANCER INSTITUTE   (United States)

^y MASSACHUSETTS GENERAL HOSPITAL   (United States)

^z H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^aa CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^ab UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^ac National Comprehensive Cancer Network   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; B RAF KINASE INHIBITOR; CHECKPOINT KINASE INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED CELL DEATH PROTEIN 1 INHIBITOR; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; DRUG EFFICACY; DRUG TARGETING; HUMAN; INOPERABLE CANCER; MELANOMA; METASTATIC MELANOMA; MONOTHERAPY; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMIC THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; CANCER STAGING; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; RETREATMENT;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; MELANOMA; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; RETREATMENT; TREATMENT OUTCOME;

EID: 84983009766     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2016.0101     Document Type: Article

References (50)

1. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16:375-384.
2. Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015;386:444-451.
3. Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015;33:2780-2788.
4. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34.
5. Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014;371:1877-1888.
6. Larkin J, Del Vecchio M, Ascierto PA, et al. Vemurafenib in patients with BRAF (V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol 2014;15:436-444.
7. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015;16:908-918.
8. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-330.
9. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015;372:30-39.
10. Johnson DB, Flaherty KT, Weber JS, et al. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol 2014;32:3697-3704.
11. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015;372:2006-2017.
12. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;372:2521-2532.
13. McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF (V600E) and BRAF (V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, openlabel study. Lancet Oncol 2014;15:323-332.
14. Larkin J, Ascierto PA, Dreno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014;371:1867-1876.
15. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995;182:459-465.
16. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-264.
17. Huard B, Prigent P, Tournier M, et al. CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. Eur J Immunol 1995;25:2718-2721.
18. Grosso JF, Kelleher CC, Harris TJ, et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest 2007;117:3383-3392.
19. Peggs KS, Quezada SA, Chambers CA, et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009;206:1717-1725.
20. Woo SR, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012;72:917-927.
21. Wang C, Thudium KB, Han M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in nonhuman primates. Cancer Immunol Res 2014;2:846-856.
22. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384:1109-1117.
23. Puzanov I, Dummer R, Schachter J, et al. Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL) [abstract]. J Clin Oncol 2015;33(Suppl): Abstract 3012.
24. Hodi FS, Gibney G, Sullivan R, et al. 23LBA An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064). Eur J Cancer 2015;51(Suppl 3):S721.
25. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723.
26. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-2526.
27. YERVOY [package insert]. Princeton, NJ: E. R. Squibb & Sons, LLC: 2015. Available at: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl. cfm?setid=2265ef30-253e-11df-8a39-0800200c9a66&type=display. Accessed February 29, 2016.
28. OPDIVO [package insert]. Princeton, NJ: Bristol-Myers Squibb Company. 2016. Available at: http://packageinserts.bms.com/pi/pi-opdivo.pdf. Accessed February 17, 2016.
29. KEYTRUDA [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2015. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2015/125514s004s006lbl.pdf. Accessed February 17, 2016.
30. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954.
31. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011;29:1239-1246.
32. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007;26:3279-3290.
33. Ekedahl H, Cirenajwis H, Harbst K, et al. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort. Br J Dermatol 2013;169:1049-1055.
34. Sala E, Mologni L, Truffa S, et al. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res 2008;6:751-759.
35. Halaban R, Zhang W, Bacchiocchi A, et al. PLX4032, a selective BRAF (V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res 2010;23:190-200.
36. Lemech C, Infante J, Arkenau HT. The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence. Ther Adv Med Oncol 2012;4:61-73.
37. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380:358-365.
38. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-714.
39. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367:107-114.
40. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-2516.
41. Kim KB, Kefford R, Pavlick AC, et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013;31:482-489.
42. Ribas A, Gonzalez R, Pavlick A, et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF (V600)-mutated melanoma: a phase 1b study. Lancet Oncol 2014;15:954-965.
43. ZELBORAF [package insert]. South San Francisco, CA: Genentech USA, Inc.; 2015. Available at: http://www.gene.com/download/pdf/zelboraf-prescribing.pdf. Accessed December 3, 2015.
44. TAFINLAR [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2015. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/tafinlar.pdf. Accessed February 17, 2016.
45. COTELLIC [package insert]. South San Francisco, CA: Genentech USA, Inc.; 2015. Available at: http://www.gene.com/download/pdf/cotellic-prescribing.pdf. Accessed November 17, 2015.
46. MEKINIST [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; Available at: http://www.pharma.us.novartis.com/product/pi/pdf/mekinist.pdf. Accessed Feb. 17, 2016.
47. Ascierto PA, Minor D, Ribas A, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 2013;31:3205-3211.
48. Hauschild A, Grob JJ, Demidov LV, et al. An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM) [abstract]. J Clin Oncol 2013;31(Suppl): Abstract 9013.
49. Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:1087-1095.
50. Pavlick AC, Ribas A, Gonzalez R, et al. Extended follow-up results of phase Ib study (BRIM7) of vemurafenib (VEM) with cobimetinib (COBI) in BRAF-mutant melanoma [abstract]. J Clin Oncol 2015;33(Suppl): Abstract 9020.